title: [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].
abstract: BACKGROUND
  Since July 2010 Ozurdex® is approved in Germany for treatment of macular edema from retinal vein occlusion (RVO). The objective of this observational study was a systemic summary and analysis of clinical experience regarding complications and side effects of intravitreal administration of dexamethasone.
  
  
  METHODS
  In a retrospective, multicenter study conducted at 10 centers, 342 eyes with RVO were treated with intravitreal dexamethasone (Ozurdex®, Allergan). After treatment the patients were followed-up over a period of 8 months and intraoperative, perioperative and postoperative complications, such as elevated intraocular pressure and dislocation of implants were systematically recorded.
  
  
  RESULTS
  No infections, endophthalmitis, perioperative hypotension, intraoperative lens injuries or retinal detachment occurred. Elevated intraocular pressure was the most common complication accounting for nearly 20 %. In 9 % of patients the intraocular pressure increased by more than 10 mmHg compared to baseline and in 6 patients to > 35 mmHg. In cases of known glaucoma intraocular pressure elevation was not significantly more frequent compared to non-glaucoma patients. In four cases a progression of lens opacity led to phacoemulsification and two implant dislocations in the anterior chamber required surgical repositioning in the vitreous cavity. In two cases a postinterventional macular hole was observed.
  
  
  CONCLUSIONS
  In the clinical routine Ozurdex treatment has proven to be a therapy method with minimal side effects. In Ozurdex administration intraocular pressure elevation was observed as the most common side effect; however, this generally did not require surgical intervention. Caution is advised in patients with an anterior chamber lens and iridectomy. Macular holes as a rare complication might result from vitreous traction during the administration process. In summary, even in the clinical routine application of Ozurdex the complication rate was not higher than in registration studies.
authors.affiliation: Augenklinik Franziskushospital Münster, Münster, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Schmitz
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.forename: C R
authors.initials: CR
authors.lastname: Clemens
authors.forename: F
authors.initials: F
authors.lastname: Höhn
authors.forename: J
authors.initials: J
authors.lastname: Wachtlin
authors.forename: F
authors.initials: F
authors.lastname: Lehmann
authors.forename: T
authors.initials: T
authors.lastname: Bertelmann
authors.forename: K
authors.initials: K
authors.lastname: Rüdiger
authors.forename: M
authors.initials: M
authors.lastname: Horn
authors.forename: A
authors.initials: A
authors.lastname: Bezatis
authors.forename: G
authors.initials: G
authors.lastname: Spital
authors.forename: C H
authors.initials: CH
authors.lastname: Meyer
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects*; D004343:Drug Implants / Q000008:administration & dosage* / Q000009:adverse effects; D009877:Endophthalmitis / Q000139:chemically induced* / Q000517:prevention & control; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000517:prevention & control; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D063173:Retrognathia; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D003907:Dexamethasone
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8
references.pmid: 18425523
references.citation: Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):80-6
references.pmid: 20702826
references.citation: Klin Monbl Augenheilkd. 2010 Sep;227(9):681-93
references.pmid: 20845248
references.citation: Retina. 2011 Jun;31(6):1028-35
references.pmid: 21836409
references.citation: Retina. 2006 May-Jun;26(5):523-30
references.pmid: 16770258
references.citation: Ophthalmology. 2012 Aug;119(8):1609-14
references.pmid: 22480743
references.citation: Retina. 2010 Oct;30(9):1524-9
references.pmid: 20664492
references.citation: Ophthalmologica. 2010;224(5):319-24
references.pmid: 20424494
references.citation: J Ocul Pharmacol Ther. 2012 Oct;28(5):547-9
references.pmid: 22537269
references.citation: Ophthalmologe. 2011 Feb;108(2):111-6
references.pmid: 21331683
references.citation: Am J Ophthalmol. 2012 Oct;154(4):682-686.e2
references.pmid: 22818800
references.citation: Ophthalmology. 2010 Jun;117(6):1124-1133.e1
references.pmid: 20381871
references.citation: Ophthalmologe. 2012 Nov;109(11):1119-21
references.pmid: 23053335
references.citation: J Ophthalmic Inflamm Infect. 2012 Mar;2(1):1-5
references.pmid: 21960148
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92
references.pmid: 21337042
references.citation: Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):155-9
references.pmid: 19763601
references.citation: Acta Ophthalmol. 2012 Mar;90(2):e98-e103
references.pmid: 22066978
references.citation: Am J Ophthalmol. 2008 Oct;146(4):573-578
references.pmid: 18639860
references.citation: Retina. 2011 Apr;31(4):662-8
references.pmid: 21836400
references.citation: Am J Ophthalmol. 2012 Feb;153(2):204-208.e1
references.pmid: 22264943
references.citation: Acta Ophthalmol. 2010 Feb;88(1):91-5
references.pmid: 19725816
references.citation: Ophthalmology. 2010 Jun;117(6):1134-1146.e3
references.pmid: 20417567
references.citation: Retina. 2011 Oct;31(9):1877-84
references.pmid: 21738089
references.citation: Acta Ophthalmol. 2011 Feb;89(1):70-5
references.pmid: 21176118
references.citation: Klin Monbl Augenheilkd. 2011 Sep;228(9):793-800
references.pmid: 21913147
references.citation: Acta Ophthalmol. 2013 Aug;91(5):e340-7
references.pmid: 23638803
references.citation: Ophthalmologe. 2007 Nov;104(11):952-7
references.pmid: 17965862
references.citation: Ophthalmology. 2009 Mar;116(3):455-60
references.pmid: 19157561
references.citation: Arch Ophthalmol. 2005 Aug;123(8):1075-7
references.pmid: 16087840
references.citation: Acta Ophthalmol. 2011 Jun;89(4):e327-31
references.pmid: 21310017
references.citation: Ophthalmology. 2008 Aug;115(8):1372-5
references.pmid: 18355920
references.citation: Retina. 2012 Nov-Dec;32(10):2133-40
references.pmid: 23060033
references.citation: Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1703-4
references.pmid: 21861084
references.citation: Ophthalmology. 2010 Feb;117(2):313-9.e1
references.pmid: 20022117
references.citation: J Ocul Pharmacol Ther. 2010 Oct;26(5):491-5
references.pmid: 20874500
references.citation: J Ocul Pharmacol Ther. 2011 Apr;27(2):197-203
references.pmid: 21314588
references.citation: Klin Monbl Augenheilkd. 2010 Jul;227(7):542-56
references.pmid: 20645226
references.citation: Retina. 2010 Feb;30(2):332-8
references.pmid: 20175274
references.citation: Ophthalmology. 2010 Jun;117(6):1102-1112.e1
references.pmid: 20398941
references.citation: Acta Ophthalmol. 2010 Dec;88(8):842-9
references.pmid: 19706019
references.citation: Retina. 2011 Nov;31(10):2032-6
references.pmid: 21659941
references.citation: Acta Ophthalmol. 2012 Jun;90(4):e322-3
references.pmid: 21939501
references.citation: Arch Ophthalmol. 2008 Apr;126(4):513-8
references.pmid: 18413521